Nisha Andany, Wayne L. Gold
Abstract
Open-access reader
Current guidelines recommend combination antiretroviral treatment for all patients with HIV infection.[1][1],[2][2] The backbone of this treatment regimen is a dual nucleoside reverse transcriptase inhibitor combination, typically tenofovir/emtricitabine or abacavir/lamivudine, which is combined
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Current guidelines recommend combination antiretroviral treatment for all patients with HIV infection.[1][1],[2][2] The backbone of this treatment regimen is a dual nucleoside reverse transcriptase inhibitor combination, typically tenofovir/emtricitabine or abacavir/lamivudine, which is combined
Key concepts: Abacavir, Emtricitabine, Lamivudine, Nucleoside Reverse Transcriptase Inhibitor, Regimen, Medicine, Tenofovir, Reverse-transcriptase inhibitor